Company Overview
About Umoja Biopharma
Umoja Biopharma is developing an in vivo CAR-T cell therapy platform that circumvents the costly and time-consuming ex vivo manufacturing process that limits current CAR-T therapies. Instead of extracting a patient's T-cells, engineering them in a lab, and reinfusing them, Umoja's approach delivers viral vectors intravenously that reprogram T-cells directly inside the patient's body. This could reduce CAR-T therapy costs from $400,000+ to a fraction of that price.
Business Model & Competitive Advantage
Founded in 2020 with deep roots in HIV cure research, Umoja's lentiviral vector technology (VivoVec) was originally developed for the gene therapy field. The company has raised over $300M and is advancing multiple oncology programs including B-cell malignancies and solid tumors through Phase 1 clinical trials. Strategic partnerships with Moderna and others validate the platform's potential.
Competitive Landscape 2025–2026
Umoja's approach addresses the core bottleneck preventing CAR-T therapies from reaching most cancer patients — manufacturing complexity and cost. If successful, in vivo CAR-T could democratize cell therapy for the estimated 100,000+ patients annually who are eligible but cannot access current approved therapies due to cost or manufacturing delays.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Umoja Biopharma is an emerging player bringing innovative solutions to the BioTech market.
Growth Stage
Umoja Biopharma has achieved $300M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
80 Acres Farms
80 Acres Farms is a commercial-scale indoor vertical farming company that, following its merger with Soli Organic, operates the largest indoor farming network in North America. The company raised $115
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Honda
Honda Motor Co., Ltd. is a Japanese multinational mobility conglomerate founded in 1948 by Soichiro Honda and Takeo Fujisawa in Hamamatsu, Japan. Starting as a motorcycle manufacturer, Honda expanded
Compare Umoja Biopharma with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Umoja Biopharma? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Umoja Biopharma Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Umoja Biopharma vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →